… Rodman has had a long career in drug development including leadership roles in translational medicine, rare disease drug … and RNA therapeutics. Dr. Rodman’s experience includes a leadership role in developing two approved medicines for CF …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
… Rodman, M.D., Chief Development Strategy Officer, assumed leadership over clinical development. Dr. Rodman joined … medicine and RNA therapeutics, having previously served in leadership roles with Novartis Institute for Biomedical …
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).